Recombinant albumin-interferon alpha-2b fusion protein (AMMS/Shanxi Kangbao Biological Product)

重组人血清白蛋白与干扰素α-2b融合蛋白（军事科学院军事医学研究院/生物制品）

Report date: 2022/10/28 20:00:50

Base Information

Drug NameRecombinant albumin-interferon alpha-2b fusion protein (AMMS/Shanxi Kangbao Biological Product)
Drug Alias Name注射用重组人血清白蛋白与干扰素α-2b融合蛋白
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanxi Kangbao Biological Product Co LtdChinese Academy Of Military Medical Sciences
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAcademy Of Military Medical SciencesShanxi Kangbao Biological Product Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A